Announcement Regarding Patent Allowance for a Long-Term Stable Formulation of DFP-10917
Filed with TSE · · 1 page · English
Summary by 6ix AI
This novel manufacturing process significantly improves stability compared to the conventional formulation, achieving over five years of stability at industrial scale. The company believes this advancement will aid in discussions with regulatory authorities regarding future approvals and clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/announcement-regarding-patent-allowance-for-a-long-term-stable-formulation-of-dfp-10917
Earlier from Delta-Fly Pharma
- Announcement Regarding the Acceptance of Two DFP-10917 Clinical Study Presentations at ASH 2026
- Update on the Phase 2/3 Clinical Trial of DFP-17729
- Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax
- Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax
- Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
Follow Delta-Fly Pharma into a list and get an email when it puts out news.
Follow Delta-Fly Pharma